Study finds cystic fibrosis drug allows patients to safely scale back lung therapies

A new multi-site study shows that people with cystic fibrosis (CF) who start the triple-drug therapy elexacaftor/tezacaftor/ivacaftor (ETI) can safely reduce many of their daily lung treatments while maintaining good health for years. "This is incredibly meaningful for individuals and families living with CF," said lead author Scott Sagel, MD, Ph.D. "For decades, people with CF have spent hours every day managing their disease. Our findings show that many have stepped back from some of those time-consuming therapies thanks to ETI." ETI helps the malfunctioning protein that causes CF work more effectively, allowing the lungs to function better from the...